<DOC>
	<DOCNO>NCT00375388</DOCNO>
	<brief_summary>The HOME-trial prospective , randomize control trial . The purpose study investigate effect metformin HCL patient type 2 diabetes mellitus intensively treated insulin quality metabolic control diabetes , daily dose insulin , lipid profile , blood pressure , incidence / progression microvascular macrovascular complication , qualify life ( Diabetes Health Profile ) . Early result publish Diabetes Care , December 2002 , page 2133-2140 .</brief_summary>
	<brief_title>The HOME Trial : Hyperinsulinaemia : Outcome Its Metabolic Effects , Randomized Controlled Trial</brief_title>
	<detailed_description>The HOME-trial prospective , randomize control trial . The purpose study investigate effect metformin HCL patient type 2 diabetes mellitus intensively treated insulin quality metabolic control diabetes , daily dose insulin , lipid profile , blood pressure , incidence / progression microvascular macrovascular complication , qualify life ( Diabetes Health Profile ) . Early result publish Diabetes Care , December 2002 , page 2133-2140 . Phase : Phase III Study Type : Interventional Overall Status : No longer recruit ( patient finish study ) Study Start Date 02 January 1998 Study Completion Date October 2002 Study Design : Study Purpose : Treatment Allocation : 1 randomize 0 non randomize Masking : Double blind Control : Placebo Assignment : Parallel Endpoints : Safety / Efficacy Primary Outcome : • To investigate quality metabolic control diabetes relate variable ( daily dose insulin , body weight ) . Secondary Outcome : - To investigate occurrence macro- microvascular complication . - To investigate quality life perform socio-economic evaluation . Conditions : Type 2 diabetes mellitus require insulin therapy . Keywords : Type 2 diabetes mellitus ; metformin ; randomize ; double-blind ; placebo-controlled ; diabetes regulation Interventions : Metformin ( 850 mg ) placebo 1-3 time daily . Insulin : 4 time daily ‘ mixture ’ 30 % rapidly 70 % slowly acting insulin , 2 time daily . Eligibility Criteria ( add main one ) Inclusion Criteria : - Patients sex ( woman menopause , woman child-bearing age sterilization practice reliable contraception ) - Type 2 DM require insulin therapy failure maximal oral antidiabetic treatment ( glycosylated Hb &gt; 7.5 % ) need exogenous insulin . ( No concomitant use oral antidiabetic agent ) - Being ambulatory - Age : 30 80 year - Proven absence Islet Antibodies , QI &lt; 28 kg/m2 - Insulin therapy 4 time daily ( 21 ) , insulin therapy 2 time daily use insulin ‘ mixture ’ ( rapidly slowly act ) - Standard dietary prescription dietician - Absence keto-acidosis - Informed consent Exclusion Criteria : - Congestive heart failure , NYHA-classes III IV - Cardiac failure and/or myocardial infarction last four month enrolment - Other severe organic / systemic disease - Metformin-induced lactic-acidosis - Intolerance metformin hydrochloride - Renal disease renal dysfunction - Hypoxic state - Severe hepatic dysfunction - Excessive alcohol intake , acute chronic - Acute chronic metabolic acidosis Gender : Both Age : 30 - 80 year Target Number Subjects : 400 ( 200 metformin , 200 placebo ) Central Contact : Name : Adriaan Kooy , internist – diabetologist Degree : MD , PhD Phone : 0528-286222 Extension : 624 Mail : kooy.a @ bethesda.nl Study Official/ Investigators Name : Adriaan Kooy Degree : MD , PhD Officials Role : Study Principal Investigator Organizational Affiliation : Bethesda Hospital Hoogeveen Dr. G.H . Amshoffweg 1 7909 AA Hoogeveen The Netherlands Locations : Facility : Bethesda Hospital Hoogeveen City : Hoogeveen State/Province : Drenthe Country : The Netherlands Recruitment Status : No longer recruit ( patient finish ) Facility : Diaconesses ’ Hospital Meppel City : Meppel State/Province : Drenthe Country : The Netherlands Recruitment Status : No longer recruit ( patient finish ) Facility : Hospital Coevorden - Hardenberg City : Coevorden State/Province : Drenthe Country : The Netherlands Recruitment Status : No longer recruit ( patient finish )</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients sex ( woman menopause , woman childbearing age sterilization practice reliable contraception ) Type 2 DM require insulin therapy failure maximal oral antidiabetic treatment ( glycosylated Hb &gt; 7.5 % ) need exogenous insulin . ( No concomitant use oral antidiabetic agent ) Being ambulatory Age : 30 80 year Proven absence Islet Antibodies , QI &lt; 28 kg/m2 Insulin therapy 4 time daily ( 21 ) , insulin therapy 2 time daily use insulin ‘ mixture ’ ( rapidly slowly act ) Standard dietary prescription dietician Absence ketoacidosis Informed consent Congestive heart failure , NYHAclasses III IV Cardiac failure and/or myocardial infarction last four month enrolment Other severe organic / systemic disease Metformininduced lacticacidosis Intolerance metformin hydrochloride Renal disease renal dysfunction Hypoxic state Severe hepatic dysfunction Excessive alcohol intake , acute chronic Acute chronic metabolic acidosis</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Metformin top insulin therapy</keyword>
	<keyword>Randomized placebo-controlled trial</keyword>
	<keyword>Diabetes regulation</keyword>
	<keyword>Daily dose insulin</keyword>
	<keyword>Body Weight</keyword>
	<keyword>Patients type 2 diabetes</keyword>
	<keyword>Intensive insulin therapy</keyword>
	<keyword>Age : 30-80 year</keyword>
	<keyword>Body mass index</keyword>
	<keyword>Lipids</keyword>
	<keyword>Blood Pressure</keyword>
	<keyword>Endothelial function</keyword>
	<keyword>Low grade inflammation</keyword>
	<keyword>Fibrinolysis</keyword>
	<keyword>Microvascular complication</keyword>
	<keyword>Macrovascular complication</keyword>
</DOC>